Feature | April 13, 2012

GE Healthcare Amyloid Plaque PET Agent Has Promising Phase 3 Results

All studies meet primary endpoints, full results to be reported later this year

April 13, 2012 — GE Healthcare announced the preliminary results of two Phase 3 studies of its investigational positron emission tomography (PET) amyloid imaging agent, F-18 flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer’s disease-associated beta amyloid brain pathology. The other study, in young healthy volunteers under age 40, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months. 

“The ability to detect or exclude significant amyloid deposits in the brain, along with other diagnostic tests, may help physicians make a more accurate assessment of patients with suspected Alzheimer’s disease (AD) and other cognitive disorders. The results from these studies are quite encouraging in demonstrating the potential of flutemetamol in that regard,” said Carl Sadowsky, M.D., clinical professor of neurology at Nova Southeastern University, Ft. Lauderdale, Fla. “We need an accurate diagnosis and better treatment, as accurate diagnosis has the potential to enable better patient management, and may also save cost.”

The accumulation of beta amyloid in the brain is believed to play a role leading up to the degeneration of neurons in AD and is one of several pathological characteristics implicated in the development of AD. Currently, AD is confirmed by histopathological identification of core features, including beta amyloid plaques, in post-mortem brain samples. Targeted amyloid imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in living humans.

“Flutemetamol may well prove to be a clinically valuable component of a broader diagnostic workup that neurologists use when assessing patients with cognitive impairments, who may have AD,” said Jonathan Allis, MI (molecular imaging) PET segment leader, GE Healthcare Medical Diagnostics. “These studies support our application for regulatory approval of flutemetamol, and we intend to file later this year.”

Flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid, and is part of a portfolio of diagnostic solutions the company is currently developing in the Alzheimer’s field. GE Healthcare is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. For example, the company is partnering with pharma to identify a biosignature, or a biological indicator, which may help physicians diagnose AD prior to the onset of clinical symptoms.

Earlier this week, the U.S. Food and Drug Administration (FDA) approved the first diagnostic agent to image Alzheimer’s disease beta-amyloid neuritic plaques in the living brain. Eli Lilly and Company and Avid Radiopharmaceuticals Inc., a wholly owned subsidiary of Lilly, released florbetapir (Amyvid), a positron emission tomography (PET) radioactive tracer agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

For more information: www.gehealthcare.com

Related Content

PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
NSCLC, lung cancer, chemotherapy, FDG PET, SNMMI 2016
News | PET Imaging | June 22, 2016
Non-small cell lung cancers (NSCLC) have a collective reputation for not responding very well to chemotherapy....
SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
Positron emission tomography (PET) with three different radiotracers can now measure amyloid plaques, tau tangles and...
Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016
News | PET Imaging | June 14, 2016
The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a ...
Philips, SNMMI 2016, Vereos digital PET/CT, time-of-flight, IntelliSpace 8.0, nuclear imaging
News | Nuclear Imaging | June 14, 2016
Philips announced it would be showcasing a variety of nuclear imaging solutions at the Society of Nuclear Medicine and...
Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration
News | Nuclear Imaging | June 09, 2016
At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens Healthineers will...
Axumin, fluciclovine F-18 injection, PET imaging agent, recurrent prostate cancer, Blue Earth Diagnostics, Siemens PETNET Solutions
Technology | Radiopharmaceuticals and Tracers | June 07, 2016
June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc.
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
FDG-PET, brain injured patients, awareness, Current Biology study

This figure shows brain glucose metabolism as evidenced by positron emission tomography with [18F]-fluorodeoxyglucose (PET-FDG) at rest in patients with chronic disorders of consciousness (vegetative state and minimally conscious patients) and fully conscious control subjects. Please notice the dramatic drop in brain glucose metabolism from full consciousness to the minimal conscious and persistent vegetative states. Image courtesy of Stender et al.

News | Nuclear Imaging | June 01, 2016
Researchers have new evidence that readily obtainable measures of the amount of glucose (sugar) consumed by the brain...
Overlay Init